Revolution Medicines, Inc.

Developing oral RAS(ON) inhibitors for RAS-addicted cancers. Daraxonrasib is under FDA review for previously treated metastatic pancreatic cancer, with additional Phase 3 programs ongoing.

Back to company catalog

Oncology · Oral RAS(ON) inhibitors · NDA under FDA review / Phase 3

Compare report options